IIL, Griffith varsity tie up to develop vaccine candidate
Company will be filing for vaccine approvals with the Indian regulator and produce it in Hyderabad
YV Phani Raj
Hyderabad 08.04.2020
Hyderabad-based vaccines maker Indian Immunologicals Limited (IIL) has commenced research to develop a vaccine for coronavirus, the pandemic that has killed more than 70,000 people across the world so far. The company has entered into an agreement with Griffith University of Australia for collaboration to conduct exploratory research to develop a lead vaccine candidate for coronavirus. As part of the collaboration, scientists from IIL and Griffith University will develop a Covid-19 vaccine using the latest codon de-optimisation technology, a gene engineering technique. The partners see promise in developing a vaccine for prophylactic, active, single dose immunisation against coronavirus in humans, with an enhanced safety profile.
Upon completion of the research, the vaccine strain will be transferred to IIL and the vaccine maker will work with the country’s regulator-CDSCO (the Central Drugs Standard Control Organisation) to further conduct clinical trials, which will be taken up in a phased manner. IIL intends to use its existing Vero cell platform technology for mass production of the virus.
(See PAGE 2)
Company will be filing for vaccine approvals with the Indian regulator and produce it in Hyderabad
YV Phani Raj
Hyderabad 08.04.2020
Hyderabad-based vaccines maker Indian Immunologicals Limited (IIL) has commenced research to develop a vaccine for coronavirus, the pandemic that has killed more than 70,000 people across the world so far. The company has entered into an agreement with Griffith University of Australia for collaboration to conduct exploratory research to develop a lead vaccine candidate for coronavirus. As part of the collaboration, scientists from IIL and Griffith University will develop a Covid-19 vaccine using the latest codon de-optimisation technology, a gene engineering technique. The partners see promise in developing a vaccine for prophylactic, active, single dose immunisation against coronavirus in humans, with an enhanced safety profile.
Upon completion of the research, the vaccine strain will be transferred to IIL and the vaccine maker will work with the country’s regulator-CDSCO (the Central Drugs Standard Control Organisation) to further conduct clinical trials, which will be taken up in a phased manner. IIL intends to use its existing Vero cell platform technology for mass production of the virus.
(See PAGE 2)
IIL, Griffith varsity tie up to develop vaccine candidate
Dr Prasanna Deshpande, Deputy Managing Director, IIL, said, “The clinical trials will be carried out in select cities of India and manufacturing will happen in one of our sites in Hyderabad.” Dr K Anand Kumar, MD, IIL, said, “IIL is committed to addressing critical public health needs by engaging in this research collaboration.”
No comments:
Post a Comment